Cholesterol in brain disease: Sometimes determinant and frequently implicated

EMBO Reports

Volumn 15, Issue 10, 2014, Pages 1036-1052

  Martín, Mauricio G ^a   Pfrieger, Frank ^b   Dotti, Carlos G ^c  

^a INSTITUTO DE INVESTIGACIÓN MÉDICA MERCEDES Y MARTÍN FERREYRA   (Argentina)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

Author keywords

Brain disease; Cholesterol metabolism; Cognition

Indexed keywords

CHOLESTEROL; OXYSTEROL; SEX HORMONE;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN DEVELOPMENT; BRAIN DISEASE; BRAIN DYSFUNCTION; BRAIN METABOLISM; CHOLESTEROL DYSHOMEOSTASIS; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; COGNITION; DISEASE ASSOCIATION; DISORDERS OF CHOLESTEROL METABOLISM; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC PREDISPOSITION; HUMAN; LONG TERM POTENTIATION; NIEMANN PICK DISEASE; PARKINSON DISEASE; PROTEIN FUNCTION; REVIEW; SMITH LEMLI OPITZ SYNDROME; SYNAPSE; SYNAPSE VESICLE; SYNAPTIC TRANSMISSION; CELL MEMBRANE; CHEMISTRY; GENETICS; HUNTINGTON CHOREA; LIPID METABOLISM; METABOLISM; MUTATION; NERVE CELL; PATHOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; CELL MEMBRANE; CHOLESTEROL; GONADAL STEROID HORMONES; HUMANS; HUNTINGTON DISEASE; LIPID METABOLISM; MUTATION; NEURONS; PARKINSON DISEASE;

EID: 84908094146     PISSN: 1469221X     EISSN: 14693178     Source Type: Journal    
DOI: 10.15252/embr.201439225     Document Type: Review

References (232)

1. Mañes S, Martínez-A C (2004) Cholesterol domains regulate the actin cytoskeleton at the leading edge of moving cells. Trends Cell Biol 14: 275-278
2. Dart C (2010) Lipid microdomains and the regulation of ion channel function. J Physiol 588: 3169-3178
3. Lippincott-Schwartz J, Phair RD (2010) Lipids and cholesterol as regulators of traffic in the endomembrane system. Annu Rev Biophys 39: 559-578
4. Simons K, Gerl MJ (2010) Revitalizing membrane rafts: new tools and insights. Nat Rev Mol Cell Biol 10: 688-699
5. Levitan I, Singh DK, Rosenhouse-Dantsker A (2014) Cholesterol binding to ion channels. Front Physiol 5: 65
6. McLean KJ, Hans M, Munro AW (2012) Cholesterol, an essential molecule: diverse roles involving cytochrome P450 enzymes. Biochem Soc Trans 40: 587-593
7. Janowski BA, Grogan MJ, Jones SA, Wisely GB, Kliewer SA, Corey EJ, Mangelsdorf DJ (1999) Structural requirements of ligands for the oxys-terol liver X receptors LXRalpha and LXRbeta. Proc Natl Acad Sci USA 96: 266-271
8. Björkhem I (2006) Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain. J Intern Med 260: 493-508
9. Radhakrishnan A, Ikeda Y, Kwon HJ, Brown MS, Goldstein JL (2007) Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: oxysterols block transport by binding to Insig. Proc Natl Acad Sci USA 104: 6511-6518
10. Gill S, Chow R, Brown AJ (2008) Sterol regulators of cholesterol homeo-stasis and beyond: the oxysterol hypothesis revisited and revised. Prog Lipid Res 47: 391-404
11. Miyoshi N, Iuliano L, Tomono S, Ohshima H (2014) Implications of cholesterol autoxidation products in the pathogenesis of inflammatory diseases. Biochem Biophys Res Commun 446: 702-708
12. Berg JM (2002) The Complex Regulation of Cholesterol Biosynthesis Takes Place at Several Levels. Biochemistry, 5th edn. New York: W.H. Freeman
13. Lev S (2010) Non-vesicular lipid transport by lipid-transfer proteins and beyond. Nat Rev Mol Cell Biol 10: 739-750
14. Ikonen E (2008) Cellular cholesterol trafficking and compartmentaliza-tion. Nat Rev Mol Cell Biol 9: 125-138
15. Storch J, Xu Z (2009) Niemann-Pick C2 (NPC2) and intracellular cholesterol trafficking. Biochim Biophys Acta 1791: 671-678
16. Brown MS, Goldstein JL (1999) A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci USA 96: 11041-11048
17. Mondal M, Mesmin B, Mukherjee S, Maxfield FR (2009) Sterols are mainly in the cytoplasmic leaflet of the plasma membrane and the endocytic recycling compartment in CHO cells. Mol Biol Cell 20: 581-588
18. Lingwood D, Simons K (2010) Lipid rafts as a membrane-organizing principle. Science 327: 46-50
19. van Meer G (2011) Dynamic transbilayer lipid asymmetry. Cold Spring Harb Perspect Biol 3: a004671
20. Gil C, Cubí R, Blasi J, Aguilera J (2006) Synaptic proteins associate with a sub-set of lipid rafts when isolated from nerve endings at physiological temperature. Biochem Biophys Res Commun 348: 1334-1342
21. Wasser CR, Kavalali ET (2009) Leaky synapses: regulation of spontaneous neurotransmission in central synapses. Neuroscience 158: 177-188
22. Mailman T, Hariharan M, Karten B (2011) Inhibition of neuronal cholesterol biosynthesis with lovastatin leads to impaired synaptic vesicle release even in the presence of lipoproteins or geranylgeraniol. J Neurochem 119: 1002-1015
23. Suzuki T (2002) Lipid rafts at postsynaptic sites: distribution, function and linkage to postsynaptic density. Neurosci Res 44: 1-9
24. Allen JA, Halverson-Tamboli RA, Rasenick MM (2007) Lipid raft microdomains and neurotransmitter signalling. Nat Rev Neurosci 8: 128-140
25. Dietschy JM, Turley SD (2004) Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. Lipid Res 45: 1375-1397
26. Pfrieger FW (2003) Cholesterol homeostasis and function in neurons of the central nervous system. Cell Mol Life Sci 60: 1158-1171
27. Björkhem I, Meaney S (2004) Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 24: 806-815
28. Russell DW, Halford RW, Ramirez DM, Shah R, Kotti T (2009) Cholesterol 24-hydroxylase: an enzyme of cholesterol turnover in the brain. Annu Rev Biochem 78: 1017-1040
29. Quan G, Xie C, Dietschy JM, Turley SD (2003) Ontogenesis and regulation of cholesterol metabolism in the central nervous system of the mouse. Brain Res Dev Brain Res 146: 87-98
30. Thelen KM, Falkai P, Bayer TA, Lütjohann D (2006) Cholesterol synthesis rate in human hippocampus declines with aging. Neurosci Lett 403: 15-19
31. Pfrieger FW, Ungerer N (2011) Cholesterol metabolism in neurons and astrocytes. Prog Lipid Res 50: 357-371
32. Porter FD, Herman GE (2011) Malformation syndromes caused by disorders of cholesterol synthesis. J Lipid Res 52: 6-34
33. Kanungo S, Soares N, He M, Steiner RD (2013) Sterol metabolism disorders and neurodevelopment-an update. Dev Disabil Res Rev 17: 197-210
34. Vanier MT (2013) Niemann-Pick diseases. Handb Clin Neurol 113: 1717-1721
35. Waterham HR, Hennekam RC (2012) Mutational spectrum of Smith-Lemli-Opitz syndrome. Am J Med Genet C Semin Med Genet 160: 263-284
36. De Barber AE, Eroglu Y, Merkens LS, Pappu AS, Steiner RD (2011) Smith-Lemli-Opitz syndrome. Expert Rev Mol Med 13: e24
37. Diaz-Stransky A, Tierney E (2012) Cognitive and behavioral aspects of Smith-Lemli-Opitz syndrome. Am J Med Genet C Semin Med Genet 160: 295-300
38. Nowaczyk MJ, Irons MB (2012) Smith-Lemli-Opitz syndrome: pheno-type, natural history, and epidemiology. Am J Med Genet C Semin Med Genet 160: 250-262
39. Cunniff C, Kratz LE, Moser A, Natowicz MR, Kelley RI (1997) Clinical and biochemical spectrum of patients with RSH/Smith-Lemli-Opitz syndrome and abnormal cholesterol metabolism. Am J Med Genet 68: 263-269
40. Cooper MK, Porter JA, Young KE, Beachy PA (1998) Teratogen-mediated inhibition of target tissue response to Shh signaling. Science 280: 1603-1607
41. Koide T, Hayata T, Cho KWY (2006) Negative regulation of Hedgehog signaling by the cholesterogenic enzyme 7-dehydrocholesterol reduc-tase. Development 133: 2395-2405
42. Porter JA, Young KE, Beachy PA (1996) Cholesterol modification of hedgehog signaling proteins in animal development. Science 274: 255-259
43. Gallet A, Ruel L, Staccini-Lavenant L, Thérond PP (2005) Cholesterol modification is necessary for controlled planar long-range activity of Hedgehog in Drosophila epithelia. Development 133: 407-418
44. Zerenturk EJ, Sharpe LJ, Ikonen E, Brown AJ (2013) Desmosterol and DHCR24: unexpected new directions for a terminal step in cholesterol synthesis. Prog Lipid Res 52: 666-680
45. Klahre U, Noguchi T, Fujioka S, Takatsuto S, Yokota T (1998) The Arabidopsis DIMINUTO/DWARF1 gene encodes a protein involved in steroid synthesis. Plant Cell 10: 1677-1690
46. Schaller H (2003) The role of sterols in plant growth and development. Prog Lipid Res 42: 163-175
47. Wu C, Miloslavskaya I, Demontis S, Maestro R, Galaktionov K (2004) Regulation of cellular response to oncogenic and oxidative stress by Seladin-1. Nature 432: 640-645
48. Greeve I, Hermans-Borgmeyer C, Brellinger D, Kasper T, Gomez-Isla T, Behl C, Levkau B, Nitsch RM (2000) The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer's disease-associated neurodegeneration and oxidative stress. J Neurosci 20: 7345-7352
49. Crameri A, Biondi E, Kuehnle K, Lütjohann D, Thelen KM, Perga S, Dotti CG, Nitsch RM, Ledesma MD, Mohajeri MH (2006) The role of sela-din-1/DHCR24 in cholesterol biosynthesis, APP processing and Abeta generation in vivo. EMBO J 25: 432-443
50. Vanier MT (2010) Niemann-Pick disease type C. Orphanet J Rare Dis 3: 16
51. Patterson MC, Hendriksz CJ, Walterfang M, Sedel F, Vanier MT, Wijburg F (2012) Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Mol Genet Metab 106: 330-344
52. Walkley SU, Suzuki K (2004) Consequences of NPC1 and NPC2 loss of function in mammalian neurons. Biochim Biophys Acta 1685: 48-62
53. Kwon HJ, Abi-Mosleh L, Wang ML, Deisenhofer J, Goldstein JL, Brown MS, Infante RE (2009) Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol. Cell 137: 1213-1224
54. Liscum L (2000) Niemann-Pick type C mutations cause lipid traffic jam. Traffic 1: 218-225
55. Vance JE, Karten B (2014) Niemann-Pick C disease and mobilization of lysosomal cholesterol by cyclodextrin. J Lipid Res 55: 1609-1621
56. Pentchev PG, Comly ME, Kruth HS, Vanier MT, Wenger DA, Patel S, Brady RO (1985) A defect in cholesterol esterification in Niemann-Pick disease (type C) patients. Proc Natl Acad Sci USA 8: 8247-8251
57. Lloyd-Evans E, Morgan AJ, He X, Smith DA, Elliot-Smith E, Sillence DJ, Churchill GC, Schuchman EH, Galione A, Platt FM (2008) Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat Med 14: 1247-1255
58. Lloyd-Evans E, Platt FM (2010) Lipids on trial: the search for the offending metabolite in Niemann-Pick type C disease. Traffic 8: 419-428
59. Liscum L, Ruggiero RM, Faust JR (1989) The intracellular transport of low density lipoprotein-derived cholesterol is defective in Niemann-Pick type C fibroblasts. J Cell Biol 108: 1625-1636
60. Karten B, Vance DE, Campenot RB, Vance JE (2002) Cholesterol accumulates in cell bodies, but is decreased in distal axons, of Niemann-Pick C1-deficient neurons. J Neurochem 83: 1154-1163
61. Ko DC, Gordon MD, Jin JY, Scott MP (2001) Dynamic movements of organelles containing Niemann-Pick C1 protein: NPC1 involvement in late endocytic events. Mol Biol Cell 12: 601-614
62. Karten B, Campenot RB, Vance DE, Vance JE (2006) The Niemann-Pick C1 protein in recycling endosomes of presynaptic nerve terminals. J Lipid Res 47: 504-514
63. Vance JE, Hayashi H, Karten B (2005) Cholesterol homeostasis in neurons and glial cells. Semin Cell Dev Biol 16: 193-212
64. Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, Zoghbi HY (2008) MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 320: 1224-1229
65. Buchovecky CM, Turley SD, Brown HM, Kyle SM, McDonald JG, Liu B, Pieper AA, Huang W, Katz DM, Russell DW et al (2013) A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome. Nat Genet 45: 1013-1020
66. Joshi HN, Fakes MG, Serajuddin ATM (1999) Differentiation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors by their relative lipophilicity. Pharm Pharmacol Commun 5: 269-271
67. Li Y, Wang H, Muffat J, Cheng AW, Orlando DA, Lovén J, Kwok SM, Feld-man DA, Bateup HS, Gao Q et al (2013) Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons. Cell Stem Cell 13: 446-458
68. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Peri-cak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ (1993) Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43: 1467-1472
69. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD (1993) Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apoli-poprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 90: 9649-9653
70. Ordovas JM, Litwack-Klein L, Wilson PW, Schaefer MM, Schaefer EJ (1987) Apolipoprotein E isoform phenotyping methodology and population frequency with identification of apoE1 and apoE5 isoforms. J Lipid Res 28: 371-380
71. Lehtinen S, Lehtimäki T, Sisto T, Salenius JP, Nikkilä M, Jokela H, Koiv-ula T, Ebeling F, Ehnholm C (1995) Apolipoprotein E polymorphism, serum lipids, myocardial infarction and severity of angiographically verified coronary artery disease in men and women. Atherosclerosis 114: 83-91
72. Howard BV, Gidding SS, Liu K (1998) Association of apolipoprotein E phenotype with plasma lipoproteins in African-American and white young adults. The CARDIA Study. Coronary Artery Risk Development in Young Adults. Am J Epidemiol 148: 859-868
73. Sparks DL, Scheff SW, Hunsaker JC 3rd, Liu H, Landers T, Gross DR (1994) Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126: 88-94
74. Zambón D, Quintana M, Mata P, Alonso R, Benavent J, Cruz-Sánchez F, Gich J, Pocoví M, Civeira F, Capurro S et al (2010) Higher incidence of mild cognitive impairment in familial hypercholesterolemia. Am J Med 123: 267-274
75. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57: 1439-1443
76. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA (2000) Statins and the risk of dementia. Lancet 356: 1627-1631
77. Reed B, Villeneuve S, Mack W, DeCarli C, Chui HC, Jagust W (2014) Associations between serum cholesterol levels and cerebral amyloido-sis. JAMA Neurol 71: 195-200
78. Altman R, Rutledge JC (2010) The vascular contribution to Alzheimer's disease. Clin Sci (Lond) 119: 407-421
79. Tenenholz Grinberg L, Thal DR (2010) Vascular pathology in the aged human brain. Acta Neuropathol 119: 277-290
80. Vasilevko V, Passos GF, Quiring D, Head E, Kim RC, Fisher M, Cribbs DH (2010) Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy. Ann N Y Acad Sci 207: 58-70
81. de la Torre JC (2004) Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 3: 184-190
82. de la Torre JC (2006) How do heart disease and stroke become risk factors for Alzheimer's disease? Neurol Res 28: 637-644
83. Newman AB, Fitzpatrick AL, Lopez O, Jackson S, Lyketsos C, Jagust W, Ives D, Dekosky ST, Kuller LH (2005) Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J Am Geriatr Soc 53: 1101-1107
84. Honig LS, Kukull W, Mayeux R (2005) Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology 64: 494-500
85. Bell RD (2012) The imbalance of vascular molecules in Alzheimer's disease. J Alzheimers Dis 32: 699-709
86. Orsucci D, Mancuso M, Ienco EC, Simoncini C, Siciliano G, Bonuccelli U (2013) Vascular factors and mitochondrial dysfunction: a central role in the pathogenesis of Alzheimer's disease. Curr Neurovasc Res 10: 76-80
87. Zhiyou C, Yong Y, Shanquan S, Jun Z, Liangguo H, Ling Y, Jieying L (2009) Upregulation of BACE1 and beta-amyloid protein mediated by chronic cerebral hypoperfusion contributes to cognitive impairment and pathogenesis of Alzheimer's disease. Neurochem Res 34: 1226-1235
88. Kitaguchi H, Tomimoto H, Ihara M, Shibata M, Uemura K, Kalaria RN, Kihara T, Asada-Utsugi M, Kinoshita A, Takahashi R (2009) Chronic cerebral hypoperfusion accelerates amyloid beta deposition in APPS-wInd transgenic mice. Brain Res 1294: 202-210
89. Poli G, Sottero B, Gargiulo S, Leonarduzzi G (2009) Cholesterol oxidation products in the vascular remodeling due to atherosclerosis. Mol Aspects Med 30: 180-189
90. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53: 474-481
91. Kruit JK, Brunham LR, Verchere CB, Hayden MR (2010) HDL and LDL cholesterol significantly influence beta-cell function in type 2 diabetes mellitus. Curr Opin Lipidol 21: 178-185
92. Ledesma MD, Dotti CG (2012) Peripheral cholesterol, metabolic disorders and Alzheimer's disease. Front Biosci (Elite Ed) 4: 181-194
93. Bu G (2009) Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 10: 333-344
94. Gong JS, Kobayashi M, Hayashi H, Zou K, Sawamura N, Fujita SC, Yana-gisawa K, Michikawa M (2002) Apolipoprotein E (ApoE) isoform-depen-dent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice. J Biol Chem 277: 29919-29926
95. Hayashi H, Campenot RB, Vance DE, Vance JE (2007) Apolipoprotein E-containing lipoproteins protect neurons from apoptosis via a signaling pathway involving low-density lipoprotein receptor-related protein-1. J Neurosci 27: 1933-1941
96. Martins IJ, Hone E, Foster JK, Sünram-Lea SI, Gnjec A, Fuller SJ, Nolan D, Gandy SE, Martins RN (2006) Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry 11: 721-736
97. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C et al (2011) Human apoE isoforms differentially regulate brain amyloid-b peptide clearance. Sci Transl Med 3: 89ra57
98. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ et al (2012) ApoE-directed therapeutics rapidly clear b-amyloid and reverse deficits in AD mouse models. Science 335: 1503-1506
99. Bien-Ly N, Gillespie AK, Walker D, Yoon SY, Huang Y (2012) Reducing human apolipoprotein E levels attenuates age-dependent Ab accumulation in mutant human amyloid precursor protein transgenic mice. J Neurosci 32: 4803-4811
100. Kanekiyo T, Xu H, Bu G (2014) ApoE and Ab in Alzheimer's disease: accidental encounters or partners? Neuron 81: 740-754
101. Zlokovic BV (2013) Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. JAMA Neurol 70: 440-444
102. Lambert JC, Amouyel P (2011) Genetics of Alzheimer's disease: new evidences for an old hypothesis? Curr Opin Genet Dev 21: 295-301
103. Silkensen JR, Schwochau GB, Rosenberg ME (1994) The role of clusterin in tissue injury. Biochem Cell Biol 72: 483-488
104. Humphreys DT, Carver JA, Easterbrook-Smith SB, Wilson MR (1999) Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem 274: 6875-6881
105. Miwa Y, Takiuchi S, Kamide K, Yoshii M, Horio T, Tanaka C, Banno M, Miyata T, Sasaguri T, Kawano Y (2005) Insertion/deletion polymorphism in clusterin gene influences serum lipid levels and carotid intima-media thickness in hypertensive Japanese females. Biochem Biophys Res Commun 331: 1587-1593
106. Rosenberg ME, Girton R, Finkel D, Chmielewski D, Barrie A 3rd, Witte DP, Zhu G, Bissler JJ, Harmony JA, Aronow BJ (2002) Apolipoprotein J/clusterin prevents a progressive glomerulopathy of aging. Mol Cell Biol 22: 1893-1902
107. Lee JY, Parks JS (2005) ATP-binding cassette transporter A1 and its role in HDL formation. Curr Opin Lipidol 16: 19-25
108. Grimm MO, Rothhaar TL, Hartmann T (2012) The role of APP proteo-lytic processing in lipid metabolism. Exp Brain Res 217: 365-375
109. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC, Mattson MP (2004) Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci USA 101: 2070-2075
110. Mulder M, Ravid R, Swaab DF, de Kloet ER, Haasdijk ED, Julk J, van der Boom JJ, Havekes LM (1998) Reduced levels of cholesterol, phospholip-ids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4. Alzheimer Dis Assoc Disord 12: 198-203
111. Kölsch H, Heun R, Jessen F, Popp J, Hentschel F, Maier W, Lütjohann D (2010) Alterations of cholesterol precursor levels in Alzheimer's disease. Biochim Biophys Acta 1801: 945-950
112. Söderberg M, Edlund C, Kristensson K, Dallner G (1990) Lipid compositions of different regions of the human brain during aging. J Neuro-chem 54: 415-423
113. Mason RP, Shoemaker WJ, Shajenko L, Chambers TE, Herbette LG (1992) Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol. Neurobiol Aging 13: 413-419
114. Roher AE, Weiss N, Kokjohn TA, Kuo YM, Kalback W, Anthony J, Watson D, Luehrs DC, Sue L, Walker D et al (2002) Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry 41: 11080-11090
115. Papassotiropoulos A, Lütjohann D, Bagli M, Locatelli S, Jessen F, Buschfort R, Ptok U, Björkhem I, von Bergmann K, Heun R (2002) 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res 36: 27-32
116. Molander-Melin M, Blennow K, Bogdanovic N, Dellheden B, Månsson JE, Fredman P (2005) Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J Neurochem 92: 171-182
117. Wang W, Mutka AL, Zmrzljak UP, Rozman D, Tanila H, Gylling H, Remes AM, Huttunen HJ, Ikonen E (2014) Amyloid precursor protein a-and b-cleaved ectodomains exert opposing control of cholesterol homeostasis via SREBP2. FASEB J 28: 849-860
118. Gylys KH, Fein JA, Yang F, Miller CA, Cole GM (2007) Increased cholesterol in Abeta-positive nerve terminals from Alzheimer's disease cortex. Neurobiol Aging 28: 8-17
119. Mori T, Paris D, Town T, Rojiani AM, Sparks DL, Delledonne A, Crawford F, Abdullah LI, Humphrey JA, Dickson DW et al (2001) Cholesterol accumulates in senile plaques of Alzheimer disease patients and in trans-genic APP(SW) mice. J Neuropathol Exp Neurol 60: 778-785
120. Pierrot N, Tyteca D, D'auria L, Dewachter I, Gailly P, Hendrickx A, Tasi-aux B, Haylani LE, Muls N, N'kuli F et al (2013) Amyloid precursor protein controls cholesterol turnover needed for neuronal activity. EMBO Mol Med 5: 608-625
121. Beel AJ, Sakakura M, Barrett PJ, Sanders CR (2010) Direct binding of cholesterol to the amyloid precursor protein: an important interaction in lipid-Alzheimer's disease relationships? Biochim Biophys Acta 1801: 975-982
122. Lütjohann D, Papassotiropoulos A, Björkhem I, Locatelli S, Bagli M, Oehring RD, Schlegel U, Jessen F, Rao ML, von Bergmann K et al (2000) Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res 41: 195-198
123. Bogdanovic N, Bretillon L, Lund EG, Diczfalusy U, Lannfelt L, Winblad B, Russell DW, Björkhem I (2001) On the turnover of brain cholesterol in patients with Alzheimer's disease. Abnormal induction of the choles-terol-catabolic enzyme CYP46 in glial cells. Neurosci Lett 314: 45-48
124. Evangelisti E, Zampagni M, Cascella R, Becatti M, Fiorillo C, Caselli A, Bagnoli S, Nacmias B, Cecchi C (2014) Plasma membrane injury depends on bilayer lipid composition in Alzheimer's disease. J Alzheimers Dis 41: 289-300
125. Ohyama Y, Meaney S, Heverin M, Ekström L, Brafman A, Shafir M, Andersson U, Olin M, Eggertsen G, Diczfalusy U et al (2006) Studies on the transcriptional regulation of cholesterol 24-hydroxylase (CYP46A1): marked insensitivity toward different regulatory axes. J Biol Chem 281: 3810-3820
126. Bordji K, Becerril-Ortega J, Buisson A (2011) Synapses, NMDA receptor activity and neuronal Ab production in Alzheimer's disease. Rev Neuro-sci 22: 285-294
127. Svennerholm L, Bostrom K, Helander CG, Jungbjer B (1991) Membrane lipids in the aging human brain. J Neurochem 56: 2051-2059
128. Svennerholm L, Boström K, Jungbjer B, Olsson L (1994) Membrane lipids of adult human brain: lipid composition of frontal and temporal lobe in subjects of age 20 to 100 years. J Neurochem 63: 1802-1811
129. Svennerholm L, Bostrom K, Jungbjer B (1997) Changes in weight and compositions of major membrane components of human brain during the span of adult human life of Swedes. Acta Neuropathol 94: 345-352
130. Fabelo N, Martín V, Santpere G, Marín R, Torrent L, Ferrer I, Díaz M (2012) Evidence for premature lipid raft aging in APP/PS1 double-trans-genic mice, a model of familial Alzheimer disease. J Neuropathol Exp Neurol 71: 868-881
131. Sodero AO, Trovò L, Iannilli F, Van Veldhoven P, Dotti CG, Martin MG (2011) Regulation of tyrosine kinase B activity by the Cyp46/cholesterol loss pathway in mature hippocampal neurons: relevance for neuronal survival under stress and in aging. J Neurochem 116: 747-755
132. Abad-Rodriguez J, Ledesma MD, Craessaerts K, Perga S, Medina M, Delacourte A, Dingwall C, De Strooper B, Dotti CG (2004) Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol 167: 953-960
133. Ledesma MD, Abad-Rodriguez J, Galvan C, Biondi E, Navarro P, Dela-courte A, Dingwall C, Dotti CG (2003) Raft disorganization leads to reduced plasmin activity in Alzheimer's disease brains. EMBO Rep 4: 1190-1196
134. Calleros L, Lasa M, Toro MJ, Chiloeches A (2006) Low cell cholesterol levels increase NFkappaB activity through a p38 MAPK-dependent mechanism. Cell Signal 18: 2292-2301
135. Zampagni M, Evangelisti E, Cascella R, Liguri G, Becatti M, Pensalfini A, Uberti D, Cenini G, Memo M, Bagnoli S et al (2010) Lipid rafts are primary mediators of amyloid oxidative attack on plasma membrane. J Mol Med (Berl) 88: 597-608
136. Pensalfini A, Zampagni M, Liguri G, Becatti M, Evangelisti E, Fiorillo C, Bagnoli S, Cellini E, Nacmias B, Sorbi S et al (2011) Membrane cholesterol enrichment prevents Ab-induced oxidative stress in Alzheimer's fibroblasts. Neurobiol Aging 32: 210-222
137. Martin MG, Perga S, Trovo L, Rasola A, Holm P, Rantamaki T, Dotti CG (2008) Cholesterol loss enhances TrkB signaling in hippocampal neurons aging in vitro. Mol Biol Cell 19: 2101-2112
138. Sodero AO, Vriens J, Ghosh D, Stegner D, Brachet A, Pallotto M, Sassoè-Pognetto M, Brouwers JF, Helms JB, Nieswandt B et al (2012) Cholesterol loss during glutamate-mediated excitotoxicity. EMBO J 31: 1764-1773
139. Teunissen CE, Floris S, Sonke M, Dijkstra CD, De Vries HE, Lütjohann D (2007) 24S-hydroxycholesterol in relation to disease manifestations of acute experimental autoimmune encephalomyelitis. J Neurosci Res 85: 1499-1505
140. Cartagena CM, Ahmed F, Burns MP, Pajoohesh-Ganji A, Pak DT, Faden AI, Rebeck GW (2008) Cortical injury increases cholesterol 24S hydroxylase (Cyp46) levels in the rat brain. J Neurotrauma 25: 1087-1098
141. Valenza M, Rigamonti D, Goffredo D, Zuccato C, Fenu S, Jamot L, Strand A, Tarditi A, Woodman B, Racchi M et al (2005) Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J Neuro-sci 25: 9932-9939
142. Leoni V, Caccia C (2014) Study of cholesterol metabolism in Huntington's disease. Biochem Biophys Res Commun 446: 697-701
143. Valenza M, Leoni V, Karasinska JM, Petricca L, Fan J, Carroll J, Pouladi MA, Fossale E, Nguyen HP, Riess O et al (2010) Cholesterol defect is marked across multiple rodent models of Huntington's disease and is manifest in astrocytes. J Neurosci 30: 10844-10850
144. Trushina E, Singh RD, Dyer RB, Cao S, Shah VH, Parton RG, Pagano RE, McMurray CT (2006) Mutant huntingtin inhibits clathrin-independent endocytosis and causes accumulation ofcholesterol in vitro and in vivo. Hum Mol Genet 15: 3578-3591
145. Futter M, Diekmann H, Schoenmakers E, Sadiq O, Chatterjee K, Rubinsztein DC (2009) Wild-type but not mutant huntingtin modulates the transcriptional activity of liver X receptors. J Med Genet 46: 438-446
146. Davie CA (2008) A review of Parkinson's disease. Br Med Bull 86: 109-127
147. Bar-On P, Rockenstein E, Adame A, Ho G, Hashimoto M, Masliah E (2006) Effects of the cholesterol-lowering compound methyl-beta-cyclodextrin in models of alpha-synucleinopathy. J Neuro-chem 98: 1032-1045
148. Koob AO, Ubhi K, Paulsson JF, Kelly J, Rockenstein E, Mante M, Adame A, Masliah E (2010) Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopa-thies. Exp Neurol 221: 267-274
149. Ghosh A, Roy A, Matras J, Brahmachari S, Gendelman HE, Pahan K (2009) Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci 29: 13543-13556
150. Rajanikant GK, Zemke D, Kassab M, Majid A (2007) The therapeutic potential of statins in neurological disorders. Curr Med Chem 14: 103-112
151. Wang Q, Yan J, Chen X, Li J, Yang Y, Weng J, Deng C, Yenari MA (2011) Statins: multiple neuroprotective mechanisms in neurodegenerative diseases. Exp Neurol 230: 27-34
152. Tsaousidou MK, Ouahchi K, Warner TT, Yang Y, Simpson MA, Laing NG, Wilkinson PA, Madrid RE, Patel H, Hentati F et al (2008) Sequence alterations within CYP7B1 implicate defective cholesterol homeostasis in motor-neuron degeneration. Am J Hum Genet 82: 510-515
153. Stiles AR, McDonald JG, Bauman DR, Russell DW (2009) CYP7B1: one cytochrome P450, two human genetic diseases, and multiple physiological functions. J Biol Chem 284: 28485-28489
154. Schüle R, Siddique T, Deng HX, Yang Y, Donkervoort S, Hansson M, Madrid RE, Siddique N, Schöls L, Björkhem I (2010) Marked accumulation of 27-hydroxycholesterol in SPG5 patients with hereditary spastic paresis. J Lipid Res 51: 819-823
155. Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW (1987) Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-contain-ing lipoproteins. Biochim Biophys Acta 917: 148-161
156. Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH (1987) Lipopro-teins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B, E (LDL) receptors in the brain. J Biol Chem 262: 14352-14360
157. Xie C, Lund EG, Turley SD, Russell DW, Dietschy JM (2003) Quantitation of two pathways for cholesterol excretion from the brain in normal mice and mice with neurodegeneration. J Lipid Res 44: 1780-1789
158. Lund EG, Guileyardo JM, Russell DW (1999) cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci USA 96: 7238-7243
159. Karu K, Hornshaw M, Woffendin G, Bodin K, Hamberg M, Alvelius G, Sjovall J, Turton J, Wang Y, Griffiths WJ (2007) Liquid chromatography-mass spectrometry utilizing multi-stage fragmentation for the identification of oxysterols. J Lipid Res 48: 976-987
160. Kotti TJ, Ramirez DM, Pfeiffer BE, Huber KM, Russell DW (2006) Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc Natl Acad Sci USA 103: 3869-3874
161. Pfeffer S, Aivazian D (2004) Targeting Rab GTPases to distinct membrane compartments. Nat Rev Mol Cell Biol 11: 886-896
162. Maioli S, Båvner A, Ali Z, Heverin M, Ismail MA, Puerta E, Olin M, Saeed A, Shafaati M, Parini P et al (2013) Is it possible to improve memory function by upregulation of the cholesterol 24S-hydroxylase (CYP46A1) in the brain? PLoS ONE 8: e68534
163. Hudry E, Van Dam D, Kulik W, De Deyn PP, Stet FS, Ahouansou O, Benraiss A, Delacourte A, Bougnères P, Aubourg P et al (2010) Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. Mol Ther 18: 44-53
164. Lehmann JM, Kliewer SA, Moore LB, Smith-Oliver TA, Oliver BB, Su JL, Sundseth SS, Winegar DA, Blanchard DE, Spencer TA et al (1997) Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem 272: 3137-3140
165. Rebeck GW (2004) Cholesterol efflux as a critical component of Alzheimer's disease pathogenesis. J Mol Neurosci 23: 219-224
166. Tall AR (2008) Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipopro-teins. J Intern Med 263: 256-273
167. Fukumoto H, Deng A, Irizarry MC, Fitzgerald ML, Rebeck GW (2002) Induction of the cholesterol transporter ABCA1 in central nervous system cells by liver X receptor agonists increases secreted Abeta levels. J Biol Chem 277: 48508-48513
168. Liang Y, Lin S, Beyer TP, Zhang Y, Wu X, Bales KR, DeMattos RB, May PC, Li SD, Jiang XC et al (2004) A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes. J Neurochem 88: 623-634
169. Matsuda A, Nagao K, Matsuo M, Kioka N, Ueda K (2013) 24(S)-hydroxy-cholesterol is actively eliminated from neuronal cells by ABCA1. J Neurochem 126: 93-101
170. Kolsch H, Lutjohann D, Tulke A, Bjorkhem I, Rao ML (1999) The neuro-toxic effect of 24-hydroxycholesterol on SH-SY5Y human neuroblas-toma cells. Brain Res 818: 171-175
171. Karasinska JM, Rinninger F, Lütjohann D, Ruddle P, Franciosi S, Kruit JK, Singaraja R, Hirsch-Reinshagen V, Fan J, Brunham LR (2009) Specific loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function. J Neurosci 29: 3579-3589
172. Karasinska JM, de Haan W, Franciosi S, Ruddle P, Fan J, Kruit JK, Stukas S, Lütjohann D, Gutmann DH, Wellington CL et al (2013) ABCA1 influences neuroinflammation and neuronal death. Neurobiol Dis 54: 445-455
173. Wang L, Schuster GU, Hultenby K, Zhang Q, Andersson S, Gustafsson JA (2002) Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration. Proc Natl Acad Sci USA 99: 13878-13883
174. Gosselet F, Saint-Pol J, Fenart L (2014) Effects of oxysterols on the blood-brain barrier: implications for Alzheimer's disease. Biochem Biophys Res Commun 446: 687-691
175. Schweinzer C, Kober A, Lang I, Etschmaier K, Scholler M, Kresse A, Sattler W, Panzenboeck U (2011) Processing of endogenous AbetaPP in blood-brain barrier endothelial cells is modulated by liver-X receptor agonists and altered cellular cholesterol homeostasis. J Alzheimers Dis 27: 341-360
176. Ehehalt R, Keller P, Haass C, Thiele C, Simons K (2003) Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 160: 113-123
177. Heverin M, Meaney S, Lütjohann D, Diczfalusy U, Wahren J, Björkhem I (2005) Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. J Lipid Res 46: 1047-1052
178. Mateos L, Ismail MA, Gil-Bea FJ, Schüle R, Schöls L, Heverin M, Folkesson R, Björkhem I, Cedazo-Mínguez A (2011) Side chain-oxidized oxysterols regulate the brain renin-angiotensin system through a liver X receptor-dependent mechanism. J Biol Chem 286: 25574-25585
179. von Bohlen und Halbach O, Albrecht D (2006) The CNS renin-angioten-sin system. Cell Tissue Res 326: 599-616
180. Pfrieger FW (2003) Role of cholesterol in synapse formation and function. Biochim Biophys Acta 1610: 271-280
181. Lentz BR, Carpenter TJ, Alford DR (1987) Spontaneous fusion of phos-phatidylcholine small unilamellar vesicles in the fluid phase. Biochemistry 26: 5389-5397
182. Jahn R, Sudhof TC (1999) Membrane fusion and exocytosis. Annu Rev Biochem 68: 863-911
183. Chernomordik LV, Kozlov MM (2003) Protein-lipid interplay in fusion and fission of biological membranes. Annu Rev Biochem 72: 175-207
184. Chen Z, Rand RP (1997) The influence of cholesterol on phospholipid membrane curvature and bending elasticity. Biophys J 73: 267-276
185. Coorssen JR, Rand RP (1990) Effects of cholesterol on the structural transitions induced by diacylglycerol in phosphatidylcholine and phosphatidylethanolamine bilayer systems. Biochem Cell Biol 68: 65-69
186. Churchward MA, Rogasevskaia T, Hofgen J, Bau J, Coorssen JR (2005) Cholesterol facilitates the native mechanism of Ca2+-triggered membrane fusion. J Cell Sci 118: 4833-4848
187. Thiele C, Hannah MJ, Fahrenholz F, Huttner WB (2000) Cholesterol binds to synaptophysin and is required for biogenesis of synaptic vesicles. Nat Cell Biol 2: 42-49
188. Linetti A, Fratangeli A, Taverna E, Valnegri P, Francolini M, Cappello V, Matteoli M, Passafaro M, Rosa P (2010) Cholesterol reduction impairs exocytosis of synaptic vesicles. J Cell Sci 123: 595-605
189. Chamberlain LH, Burgoyne RD, Gould GW (2001) SNARE proteins are highly enriched in lipid rafts in PC12 cells: implications for the spatial control of exocytosis. Proc Natl Acad Sci USA 98: 5619-5624
190. Kudinov AR, Kudinova NV, Berezov TT (2006) Cholesterol is an important molecule in the processes of the synaptic plasticity and degeneration of neurons. Vestn Ross Akad Med Nauk 2006: 61-66
191. Mauch DH, Nägler K, Schumacher S, Göritz C, Müller EC, Otto A, Pfrie-ger FW (2001) CNS synaptogenesis promoted by glia-derived cholesterol. Science 294: 1354-1357
192. Göritz C, Mauch DH, Pfrieger FW (2005) Multiple mechanisms mediate cholesterol-induced synaptogenesis in a CNS neuron. Mol Cell Neurosci 29: 190-201
193. Lang T, Bruns D, Wenzel D, Riedel D, Holroyd P, Thiele C, Jahn R (2001) SNAREs are concentrated in cholesterol-dependent clusters that define docking and fusion sites for exocytosis. EMBO J 20: 2202-2213
194. Chamberlain LH, Gould GW (2002) The vesicle-and target-SNARE proteins that mediate Glut4 vesicle fusion are localized in detergent-insoluble lipid rafts present on distinct intracellular membranes. J Biol Chem 277: 49750-49754
195. Dason JS, Smith AJ, Marin L, Charlton MP (2014) Cholesterol and F-actin are required for clustering of recycling synaptic vesicle proteins in the presynaptic plasma membrane. J Physiol 592: 621-633
196. Bliss TV, Collingridge GL (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361: 31-39
197. Malinow R, Malenka RC (2002) AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci 25: 103-126
198. Malenka RC (2003) Synaptic plasticity and AMPA receptor trafficking. Ann N Y Acad Sci 1003: 1-11
199. Plant K, Pelkey KA, Bortolotto ZA, Morita D, Terashima A, McBain CJ, Collingridge GL, Isaac JT (2006) Transient incorporation of native GluR2-lacking AMPA receptors during hippocampal long-term potentia-tion. Nat Neurosci 9: 602-604
200. Choquet D, Triller A (2003) The role of receptor diffusion in the organization of the postsynaptic membrane. Nat Rev Neurosci 4: 251-265
201. Bard L, Groc L (2011) Glutamate receptor dynamics and protein interaction: lessons from the NMDA receptor. Mol Cell Neurosci 48: 298-307
202. Sheng M, Hoogenraad CC (2007) The postsynaptic architecture of excitatory synapses: a more quantitative view. Annu Rev Biochem 76: 823-847
203. Renner M, Choquet D, Triller A (2009) Control of the postsynaptic membrane viscosity. J Neurosci 29: 2926-2937
204. Hering H, Lin CC, Sheng M (2003) Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. J Neurosci 23: 3262-3271
205. Martin MG, Ahmed T, Korovaichuk A, Venero C, Menchón SA, Salas I, Munck S, Herreras O, Balschun D, Dotti CG (2014) Constitutive hippo-campal cholesterol loss underlies poor cognition in old rodents. EMBO Mol Med 6: 902-917
206. Frank C, Giammarioli AM, Pepponi R, Fiorentini C, Rufini S (2004) Cholesterol perturbing agents inhibit NMDA-dependent calcium influx in rat hippocampal primary culture. FEBS Lett 566: 25-29
207. Frank C, Rufini S, Tancredi V, Forcina R, Grossi D, D'Arcangelo G (2008) Cholesterol depletion inhibits synaptic transmission and synaptic plasticity in rat hippocampus. Exp Neurol 212: 407-414
208. Paul SM, Doherty JJ, Robichaud AJ, Belfort GM, Chow BY, Hammond RS, Crawford DC, Linsenbardt AJ, Shu HJ, Izumi Y et al (2013) The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors. J Neurosci 33: 17290-17300
209. Trovò L, Ahmed T, Callaerts-Vegh Z, Buzzi A, Bagni C, Chuah M, Vandendriessche T, D'Hooge R, Balschun D, Dotti CG (2013) Low hippo-campal PI(4, 5)P(2) contributes to reduced cognition in old mice as a result of loss of MARCKS. Nat Neurosci 16: 449-455
210. Iannilli F, Sodero AO, Ledesma MD, Dotti CG (2011) Oxidative stress activates the pro-survival TrkA pathway through membrane cholesterol loss. Neurobiol Aging 32: 1033-1042
211. Martin MG, Trovò L, Perga S, Sadowska A, Rasola A, Chiara F, Dotti CG (2011) Cyp46-mediated cholesterol loss promotes survival in stressed hippocampal neurons. Neurobiol Aging 32: 933-943
212. Liu B, Li H, Repa JJ, Turley SD, Dietschy JM (2008) Genetic variations and treatments that affect the lifespan of the NPC1 mouse. J Lipid Res 49: 663-669
213. Davidson CD, Ali NF, Micsenyi MC, Stephney G, Renault S, Dobrenis K, Ory DS, Vanier MT, Walkley SU (2009) Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS ONE 4: e6951
214. Ottinger EA, Kao ML, Carrillo-Carrasco N, Yanjanin N, Shankar RK, Janssen M, Brewster M, Scott I, Xu X, Cradock J et al (2014) Collaborative development of 2-hydroxypropyl-b-cyclodextrin for the treatment of Niemann-Pick type C1 disease. Curr Top Med Chem 14: 330-339
215. Yao J, Ho D, Calingasan NY, Pipalia NH, Lin MT, Beal MF (2012) Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease. J Exp Med 209: 2501-2513
216. Porter FD, Scherrer DE, Lanier MH, Langmade SJ, Molugu V, Gale SE, Olzeski D, Sidhu R, Dietzen DJ, Fu R et al (2010) Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med 2: 56-81
217. Jiang X, Sidhu R, Porter FD, Yanjanin NM, Speak AO, te Vruchte DT, Platt FM, Fujiwara H, Scherrer DE, Zhang J et al (2011) A sensitive and specific LC-MS/MS method for rapid diagnosis of Niemann-Pick C1 disease from human plasma. J Lipid Res 52: 1435-1445
218. Sodhi RK, Singh N (2014) Liver X receptor activation by the agonist T0901317 reduces neuropathological changes and improves memory in mouse models of experimental dementia. Eur J Pharmacol 732: 50-59
219. Donkin JJ, Stukas S, Hirsch-Reinshagen V, Namjoshi D, Wilkinson A, May S, Chan J, Fan J, Collins J, Wellington CL (2010) ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin1 mice. J Biol Chem 285: 34144-34154
220. Fitz NF, Castranio EL, Carter AY, Kodali R, Lefterov I, Koldamova R (2014) Improvement of memory deficits and amyloid-b clearance in aged APP23 mice treated with a combination of anti-amyloid-b antibody and LXR agonist. J Alzheimers Dis 41: 535-549
221. Terwel D, Steffensen KR, Verghese PB, Kummer MP, Gustafsson JÅ, Holtzman DM, Henekea MT (2011) Critical role of astroglial apolipopro-tein E and liver X receptor-a expression for microglial Ab phagocytosis. J Neurosci 31: 7049-7059
222. Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE (2007) Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med 5: 20
223. Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD (2008) Use of statins and incidence of dementia and cognitive impairmentwithout dementia in a cohort study. Neurology 71: 344-350
224. Wong WB, Lin VW, Boudreau D, Devine EB (2013) Statins in the prevention of dementia and Alzheimer's disease: a meta-analysis of observational studies and an assessment of confounding. Pharmacoepi-demiol Drug Saf 22: 345-358
225. Trompet S, van Vliet P, de Craen AJ, Jolles J, Buckley BM, Murphy MB, Ford I, Macfarlane PW, Sattar N, Packard CJ et al (2010) Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol 257: 85-90
226. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM (2003) Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 23: 871-880
227. Schilling JM, Cui W, Godoy JC, Risbrough VB, Niesman IR, Roth DM, Patel PM, Drummond JC, Patel HH, Zemljic-Harpf AE et al (2014) Long-term atorvastatin treatment leads to alterations in behavior, cognition, and hippocampal biochemistry. Behav Brain Res 267: 6-11
228. Shepardson NE, Shankar GM, Selkoe DJ (2011) Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch Neurol 68: 1385-1392
229. Chu LW, Chen JY, Yu KL, Cheng KI, Wu PC, Wu BN (2012) Neuropro-tective and anti-inflammatory activities of atorvastatin in a rat chronic constriction injury model. Int J Immunopathol Pharmacol 25: 219-230
230. Laufs U, Gertz K, Dirnagl U, Böhm M, Nickenig G, Endres M (2002) Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endo-thelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 942: 23-30
231. Puttananjaiah MK, Dhale MA, Gaonkar V, Keni S (2011) Statins: 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors demonstrate anti-atherosclerotic character due to their antioxidant capacity. Appl Biochem Biotechnol 163: 215-222
232. Vance JE (2012) Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. Dis Model Mech 5: 746-755